[Vaccine] Information

Lorem ipsum dolor sit amet, consectetur adipiscing elit. In eleifend ullamcorper leo, at semper libero consectetur et. Ut eget ligula posuere, laoreet diam scelerisque, molestie ex. Phasellus pulvinar mollis lectus at volutpat. Mauris rhoncus hendrerit consectetur. In eu nunc in ligula suscipit pretium at non turpis. Quisque id augue non lectus bibendum consectetur. In ultricies erat in tristique porta. Morbi rhoncus diam id rhoncus scelerisque.

Additional Info


Lorem ipsum dolor sit amet.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. In eleifend ullamcorper leo, at semper libero consectetur et.

Nulla dapibus nisl quis consectetur rhoncus. Vestibulum non interdum elit, ut congue enim. Cras aliquet tellus lectus, rhoncus ornare mauris laoreet non. Quisque lacus nunc, suscipit vel tempus nec, porttitor eu erat. Phasellus lacinia vel sapien non tincidunt. Integer in elementum turpis. Vestibulum ante ipsum primis in faucibus orci luctus et ultrices posuere cubilia curae; In dapibus, ante ac fermentum elementum, nisl sem efficitur tortor, ac lacinia eros enim in odio.1

Lorem ipsum dolor sit amet, consectetur adipiscing elit. In eleifend ullamcorper leo, at semper libero consectetur et. Ut eget ligula posuere, laoreet diam scelerisque, molestie ex. Phasellus pulvinar mollis lectus at volutpat. Mauris rhoncus hendrerit consectetur. In eu nunc in ligula suscipit pretium at non turpis. Quisque id augue non lectus bibendum consectetur. In ultricies erat in tristique porta. Morbi rhoncus diam id rhoncus scelerisque.

Nulla dapibus nisl quis consectetur rhoncus. Vestibulum non interdum elit, ut congue enim. Cras aliquet tellus lectus, rhoncus ornare mauris laoreet non. Quisque lacus nunc, suscipit vel tempus nec, porttitor eu erat. Phasellus lacinia vel sapien non tincidunt. Integer in elementum turpis. Vestibulum ante ipsum primis in faucibus orci luctus et ultrices posuere cubilia curae; In dapibus, ante ac fermentum elementum, nisl sem efficitur tortor, ac lacinia eros enim in odio.

Lorem ipsum dolor sit amet.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. In eleifend ullamcorper leo, at semper libero consectetur et.

Nulla dapibus nisl quis consectetur rhoncus. Vestibulum non interdum elit, ut congue enim. Cras aliquet tellus lectus, rhoncus ornare mauris laoreet non. Quisque lacus nunc, suscipit vel tempus nec, porttitor eu erat. Phasellus lacinia vel sapien non tincidunt. Integer in elementum turpis. Vestibulum ante ipsum primis in faucibus orci luctus et ultrices posuere cubilia curae; In dapibus, ante ac fermentum elementum, nisl sem efficitur tortor, ac lacinia eros enim in odio.1

Lorem ipsum dolor sit amet, consectetur adipiscing elit. In eleifend ullamcorper leo, at semper libero consectetur et. Ut eget ligula posuere, laoreet diam scelerisque, molestie ex. Phasellus pulvinar mollis lectus at volutpat. Mauris rhoncus hendrerit consectetur. In eu nunc in ligula suscipit pretium at non turpis. Quisque id augue non lectus bibendum consectetur. In ultricies erat in tristique porta. Morbi rhoncus diam id rhoncus scelerisque.

Nulla dapibus nisl quis consectetur rhoncus. Vestibulum non interdum elit, ut congue enim. Cras aliquet tellus lectus, rhoncus ornare mauris laoreet non. Quisque lacus nunc, suscipit vel tempus nec, porttitor eu erat. Phasellus lacinia vel sapien non tincidunt. Integer in elementum turpis. Vestibulum ante ipsum primis in faucibus orci luctus et ultrices posuere cubilia curae; In dapibus, ante ac fermentum elementum, nisl sem efficitur tortor, ac lacinia eros enim in odio.


1. Rosenblum HG, Gee J, Liu R, et al. Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe. Lancet. March 7, 2022. DOI:https://doi.org/10.1016/S1473-3099(22)00054-8.

2. U.S. Food and Drug Administration. FDA Approves First COVID-19 Vaccine. Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine.

3. Centers for Disease Control and Prevention (CDC). COVID-19 Vaccines for Children and Teens. June 19, 2022. Available at: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/children-teens.html

4. Centers for Disease Control and Prevention (CDC). Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States. March 2, 2022. Available at: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html.

5. U.S. Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals. May 5, 2022. Available at: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-limits-use-janssen-covid-19-vaccine-certain-individuals.

6. Centers for Disease Control and Prevention (CDC). Stay Up to Date with COVID-19 Vaccines Including Boosters. September 8, 2022. Available at: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/stay-up-to-date.html.

7. Centers for Disease Control and Prevention (CDC). New COVID-19 Vaccine Effectiveness Data Showcase Protection Gained by 3rd and 4th Doses. July 15, 2022. Available at: https://www.cdc.gov/media/releases/2022/s0715-COVID-VE.html.

8. Danza P, Koo TH, Haddix M, et al. SARS-CoV-2 Infection and Hospitalization Among Adults Aged ≥18 Years, by Vaccination Status, Before and During SARS-CoV-2 B.1.1.529 (Omicron) Variant Predominance — Los Angeles County, California, November 7, 2021–January 8, 2022. MMWR Morb Mortal Wkly Rep. 2022;71:177–181. DOI: http://dx.doi.org/10.15585/mmwr.mm7105e1.

9. Link-Gelles R, Levy ME, Gaglani M, et al. Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated — VISION Network, 10 States, December 2021–June 2022. MMWR Morb Mortal Wkly Rep. 2022;71:931–939. DOI: http://dx.doi.org/10.15585/mmwr.mm7129e1.

10. Kuodi P, Gorelik Y, Zayyad H, et al. Association between vaccination status and reported incidence of post-acute COVID-19 symptoms in Israel: a cross-sectional study of patients tested between March 2020 and November 2021. medRxiv. January 17, 2022. doi: https://doi.org/10.1101/2022.01.05.22268800.

11. Ayoubkhani D, Bermingham C, Pouwels KB, et al. Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study. BMJ. 2022;377:e069676.

12. Taghioff SM, Slavin BR, Holton T, Singh D. Examining the potential benefits of the influenza vaccine against SARS-CoV-2: A retrospective cohort analysis of 74,754 patients. PLoS One. 2021;16(8):e0255541.

13. Tayar E, Abdeen S, Alah MA, et al. Effectiveness of influenza vaccination against SARS-Co-V-2 infection among healthcare workers in Qatar. Preprint at medRxiv: doi: https://doi.org/10.1101/2022.05.09.22274802.

COVID-19 FAQs

For additional questions, consult with your health care provider.

Last updated September 29, 2022

  • For the vast majority of people, the benefits of preventing a COVID-19 infection outweigh any risks of the vaccine. The vaccine helps protect you from getting COVID-19 and is considered a safe way to build protection against the disease. COVID-19 can have serious, life-threatening complications, and there is no way to know how COVID-19 will affect you or your loved ones. If you still get infected, the vaccine may prevent serious illness and death. By getting vaccinated, you are helping to protect yourself, your family and friends.

  • Currently, all COVID-19 vaccines authorized in the U.S. have proved to be highly effective against preventing severe disease, hospitalization, and death from COVID-19. Data show that the mRNA vaccines (Pfizer-BioNTech or Moderna) also provide protection against variants of the virus, including the Omicron strains. While there is lower vaccine effectiveness against infection and symptomatic disease caused by the Omicron variants, the breakthrough infections occurring in those with up-to-date vaccination are associated with fewer hospitalizations and deaths.

  • The vaccines currently available in the U.S. include Pfizer-BioNTech, Moderna, Johnson & Johnson/Janssen, and Novavax. All U.S. COVID-19 vaccines have passed the same rigorous review process, and all are highly effective in preventing hospitalizations and deaths from COVID-19. Generally, mRNA vaccines are recommended as a first option due to their excellent safety profiles and effectiveness. The Johnson & Johnson/Janssen vaccine should be reserved for individuals who are unable to take an mRNA vaccine due to medical contraindications or local supply constraints. If you have concerns about your medical condition(s) and receiving the vaccine, consult with your physician.

  • The timing between your initial and second vaccine dose depends on which vaccine you received. If you received either Pfizer-BioNTech or Moderna, you should have received your second dose near the recommended 3-week or 1-month interval when possible. If for some reason you did not get the second dose at 3-4 weeks after the first, then it is recommended that you get the second dose at the earliest opportunity to do so. You should not receive the second dose earlier than the recommended interval. The second dose of an mRNA vaccine may be given at no less than 3 weeks (for Pfizer-BioNTech) or 4 weeks (Moderna). An 8-week interval may be optimal for some people ages 12 years and older, especially for males ages 12 to 39 years. The Novavax vaccine is a newer two-dose vaccine given 3-8 weeks apart. This information does not apply to the Johnson & Johnson/Janssen vaccine. See below for additional information on booster dose(s).

  • Vaccine recommendations are based on your age, the vaccine you first received, and the time since last dose. Individuals 18 years of age and older are eligible for the Moderna updated bivalent (Omicron) booster dose if it has been at least 2 months since they have completed primary vaccinations, or have received the most recent booster dose with any authorized or approved COVID-19 vaccine. Individuals 12 years of age and older are eligible for Pfizer-BioNTech updated bivalent (Omicron) booster dose if it has been at least 2 months since they have completed primary vaccination, or have received the most recent booster dose with any authorized or approved COVID-19 vaccine. Eligible individuals may choose which vaccine they receive as a booster dose. CDC allows for a booster dose that is not the same type as the initial vaccination(s). Novavax was only approved as a primary vaccine, not as a booster, at least so far.

  • The same technology was used for the bivalent (Omicron) booster as the primary vaccine series, which has shown a good safety profile. The updated bivalent (Omicron) booster is similar to the influenza vaccine covering multiple strains of the virus.

  • For anyone who has been infected with COVID-19, their next dose may be delayed up to 3 months from when symptoms started or, if they did not have symptoms, when they received a positive test. This possible delay can happen with a primary dose or a booster dose. Consult your physician if you have any questions about the timing of your primary or booster dose.

Other Vaccine Information

  • Influenza

    Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean volutpat velit lorem, at pretium risus euismod eu. Donec quis lorem nec quam accumsan imperdiet.

  • Monkeypox

    Morbi ultricies sapien elit, non gravida justo rutrum at. In hac habitasse platea dictumst. Nunc a purus blandit, aliquam nulla sed, porta velit.

  • Work/Travel Related

    Aenean finibus quam ipsum, non rhoncus lectus fringilla non. Etiam sapien est, egestas vitae leo vehicula.

  • Other

    Laoreet finibus libero. Mauris tincidunt, ipsum at euismod venenatis, mi orci porttitor est, eget tincidunt risus diam quis lacus.